Expert oncologists share insight on the prognosis of triple-negative breast cancer (TNBC) and broadly review current treatment options for patients.
7,9,10 Another major concern in TNBC is its inherent inter-tumoral heterogeneity with different TNBC subtypes: basal-like 1 (BL1), basal-like 2 (BL2), mesenchymal (M), and luminal androgen receptor (LAR).11,12 Interestingly, HER2-low breast cancer is associated with the...
Skip to main contentSkip to article Journals & Books Help
What challenges remain in TNBC? Patients with this disease, particularly those with metastatic TNBC, still have a poor prognosis. The therapies that are available, particularly the chemotherapy [regimens], still offer a short PFS. Anything that can be done to improve the targeted therapies and imp...
Generally, when we see results that are this significant, we would expect all the subgroups to derive benefit, and this is exactly what was seen in all the subgroups, including patients who did not have an initial diagnosis of TNBC. This is something we see in clinical practice—patients who...
for example. This has been reported at ASCO, and we will subsequently do a what we call a multivariate analysis to see if there if we can understand this better. But it certainly has raised awareness within our network that we need to identify all patients that are appropriate for testing....
[20,21]. What is actually unclear is why BER could be directly involved in the CDDP- induced DNA damage, since it is not able to process any bulky DNA distortion produced by Pt-induced adducts. Interestingly, several authors have hypothesized an indirect involvement of BER in mediating ...
Oncology Frontier:What do you think is the reason for that results for this study? And what can we learn from this study for the treatment of TNBC patients? Heather McArthur:I suspect that this was a negative study because of the adjuvant administration at the checkpoint inhibitor. I think ...
Two-faced activity of RNF8: what “twists” it from a genome guardian to a cancer facilitator? Mol. Cell. Oncol. 3, e1242454 (2016). Article Google Scholar Ruan, D. et al. Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by de...
Oncology Frontier:What do you think is the reason for that results for this study? And what can we learn from this study for the treatment of TNBC patients? Heather McArthur:I suspect that this was a negative study ...